Drug intelligence / Profile preview

warfarin + enoxaparin

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral, Subcutaneous
01

Overview

The combination of warfarin and enoxaparin is a therapeutic anticoagulant regimen used primarily for the treatment of deep vein thrombosis (DVT) and related conditions. This is not a single formulated drug product but rather a combination therapy where both medications are administered concurrently during a transitional period of anticoagulation management. ## Therapeutic Use Warfarin and enoxaparin are commonly used together in a sequential therapy approach. Enoxaparin provides immediate anticoagulation while warfarin, which has a delayed onset of action, gradually reaches therapeutic levels. This combination is specifically indicated for: - Treatment of deep vein thrombosis with or without pulmonary embolism - Management of acute thrombotic conditions requiring immediate and sustained anticoagulation ## Mechanism of Action The combination works through complementary mechanisms: - **Warfarin**: A vitamin K antagonist that inhibits the synthesis of clotting factors II, VII, IX, and X, as well as the anticoagulant proteins C and S - **Enoxaparin**: A low molecular weight heparin that enhances the activity of antithrombin III, inhibiting factor Xa and thrombin ## Administration Protocol When used together: - Enoxaparin is typically initiated immediately - Warfarin therapy is started within 72 hours of beginning enoxaparin - Enoxaparin is continued for a minimum of 5 days and until warfarin achieves a therapeutic INR (2.0-3.0) - The average duration of enoxaparin administration is 7 days, though up to 17 days has been used in clinical trials ## Safety Considerations This combination requires careful monitoring due to: - Increased risk of bleeding complications - Need for regular INR monitoring to adjust warfarin dosing - Potential drug interactions affecting anticoagulation intensity Compared to other anticoagulant combinations, warfarin has a higher drug-drug interaction potential than direct oral anticoagulants, while enoxaparin has fewer drug-drug interactions than other options.

Brand names
LovenoxCoumadinJantoven
Other names
enoxaparin sodiumwarfarin sodium
02

Targets

F2 (Thrombin)VKORC1 (Vitamin K epoxide reductase complex subunit 1)ATIII (Antithrombin III)F10 (Factor Xa)

Beyond the preview

Go deeper on warfarin + enoxaparin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on warfarin + enoxaparin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call